Fosamax Related Published Studies
Well-designed clinical trials related to Fosamax (Alendronate)
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). [2008.10]
The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. [2008.10]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.09.20]
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [2008.09.20]
Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial). [2008.07.18]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2008.06.07]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]
The effect of alendronate on progression of spinal osteophytes and disc space narrowing. [2008.02.14]
Alendronate decreases TRACP 5b activity in osteoarthritic bone. [2008.01.23]
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]
Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K(2) in postmenopausal women. [2008]
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. [2007.11.30]
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. [2007.11.15]
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. [2007.07]
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. [2007.06]
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. [2007.05]
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. [2007.05]
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. [2007.04]
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. [2007.03.20]
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). [2007.03]
Application of a semi-automated 96-well format solid-phase extraction, column-switching, fluorescence detection protocol for the determination of alendronate in human urine samples obtained from a bioequivalence study. [2007.02.19]
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. [2007.01]
Alendronate inhibits periprosthetic bone loss around uncemented femoral components. [2007]
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. [2007]
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. [2006.12.27]
Effects of a combined alendronate and calcitriol agent (Maxmarvil(R)) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006.12]
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. [2006.09]
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. [2006.08.17]
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. [2006.08]
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. [2006.08]
Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. [2006.07]
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006.07]
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. [2006.07]
[Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients] [2006.07]
Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. [2006.06]
Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. [2006.05]
Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. [2006.03]
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. [2006.03]
Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3-Year Randomized Placebo-Controlled Trial. [2006.02]
Three-year changes in bone mineral density around the knee after a six-month course of oral alendronate following total knee arthroplasty. A prospective, randomized study. [2006.02]
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. [2006.02]
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. [2006.01]
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. [2006.01]
In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. [2006]
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. [2006]
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. [2006]
Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. [2005.12.31]
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
Alendronate for osteoporosis in men with androgen-repleted hypogonadism. [2005.12]
Impact of alendronate on quality of life in children with osteogenesis imperfecta. [2005.11]
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. [2005.11]
The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. [2005.10]
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. [2005.10]
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. [2005.10]
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. [2005.09]
Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. [2005.09]
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. [2005.09]
Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. [2005.09]
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. [2005.09]
Daily and cyclic parathyroid hormone in women receiving alendronate. [2005.08.11]
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. [2005.08.11]
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. [2005.08.08]
Effects of short-term alendronate on bone mineral density in haemodialysis patients. [2005.08]
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. [2005.08]
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. [2005.07]
Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. [2005.07]
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. [2005.07]
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. [2005.06]
Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. [2005.06]
Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. [2005.06]
Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. [2005.06]
Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. [2005.05]
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. [2005.04.01]
Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. [2005.04]
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. [2005.03.01]
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. [2005.03]
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. [2005.03]
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. [2005.02.18]
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. [2005.01]
Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. [2005.01]
Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. [2005.01]
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. [2005]
In vitro and in vivo equivalence studies of alendronate monosodium tablets. [2005]
Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. [2004.12]
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. [2004.12]
Changes in bone density and turnover after alendronate or estrogen withdrawal. [2004.11]
Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. [2004.11]
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. [2004.10]
Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. [2004.09.01]
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. [2004.09]
Bioequivalence study of clopidogrel bisulfate film-coated tablets. [2004.09]
Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-month follow-up of a randomized, controlled trial. [2004.09]
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. [2004.08]
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. [2004.08]
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. [2004.07.19]
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. [2004.07.15]
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. [2004.07]
Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. [2004.07]
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. [2004.07]
Prevention of bone loss in paraplegics over 2 years with alendronate. [2004.07]
|
